secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lexaria Bioscience Corp. (LEXX)
CIK:        0001348362
Form:       8-K
Filed at:   2022-08-12T23:59:59+00:00
Accession:  0001640334-22-001756
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 1.0, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lexaria enters $5.925M at-the-market equity distribution agreement with Maxim Group
--------------------------------------------------------------------------------

- Aggregate offering price of up to $5,925,000 of common stock through Maxim Group as distribution agent.
- Sales made at market pursuant to existing S-3 registration statement (effective Feb. 4, 2022).
- Commission of 3% of gross proceeds paid to Maxim; Company also reimburses certain expenses.
- Company not obligated to sell any shares; termination on sale completion or agreement termination.
- Agreement contains customary representations, warranties, and indemnification provisions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1348362/000164033422001756/0001640334-22-001756-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1348362/000164033422001756/lxrp_8k.htm
  HTML page:      https://secwatch.observer/filing/0001640334-22-001756

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer